Any current/future new fundraising through debt or equity?

No new fundraising through debt or equity is mentioned in the transcript. The company has repaid Rs.100 crore of working capital loans during H1 FY24. Post this repayment, Rallis India has become a zero-debt company except for a small sales tax deferral loan. Capex for the year is envisaged to be around Rs.150 crore, indicating ongoing investments are likely to be funded internally. No indication of plans for raising additional capital through equity or new debt issuance was shared during the call.

Any current/future capex/capital investment/strategic investment?

The company envisages capex spending of around Rs.150 crore for the year. Focus on ramping up the multipurpose plant (MPP) at Dahej. Continuous evaluation and potential expansion of capacity for Pendimethalin due to rising demand. Investments made over the last few years in R&D, product development, manufacturing, and capabilities aimed at supporting long-term sustainable growth. Plans to scale up contract manufacturing business progressively through better utilization of the new multi-purpose plant. Introduction of new technical products like Difenoconazole and upcoming commercialization of n

Future growth expectations in sales/revenue/volumes?

The global agrochemical business experienced rapid growth (from $60-65 billion to $80 billion in two years) but is currently facing inventory overhang and price correction, causing demand compression expected to last through Q3 and the financial year. Volume-led growth is a priority, though pricing growth is likely negative in the near term. Domestic industry growth is expected to be low single digit with flat to marginally positive volumes. International business faces volume declines due to high channel inventories and pricing pressures, with normalization anticipated after Q3 but timi

Future growth expectations in earnings/operating earnings/profits/EPS?

Near-term challenges expected to continue well into Q3 and possibly for the rest of the financial year due to sharp price corrections, global demand compression, and inventory overhang. Pricing growth likely to be negative with focus on volume-led growth across portfolio. Margins remain a priority; improvement targeted via better product mix and pricing actions. Long-term growth driven by investments in R&D, product development, manufacturing, and capabilities. New product launches and strategic initiatives (e.g., multipurpose plant ramp-up, Difenoconazole commercialization) expected t

IN US

Sale is live|00:00:00left today

Rallis India LtdQ3 FY23Fertilizers & Agrochemicals

Rallis India Ltd Q3 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹231P/E: 25.6Market Cap: ₹5.2K CrSector: Fertilizers & Agrochemicals

Management growth scorecard

Revenue

Category 5

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 5

→The global agrochemical business experienced rapid growth (from $60-65 billion to $80 billion in two years) but is currently facing inventory overhang and price correction, causing demand compression expected to last through Q3 and the financial year.
→Volume-led growth is a priority, though pricing growth is likely negative in the near term.
→Domestic industry growth is expected to be low single digit with flat to marginally positive volumes.
→International business faces volume declines due to high channel inventories and pricing pressures, with normalization anticipated after Q3 but timing uncertain.
→Seed business growth is positive with strong cotton hybrid sales; efforts continue to reduce seasonality and improve unit economics.
→New product launches, ramp-up of multipurpose plants, and strategic pipeline development aim for steady consistent growth over the coming years.
→Cost and margin management remain priorities to navigate volatile markets and sustain profitability.

Margin guidance

Category 3

→Near-term challenges expected to continue well into Q3 and possibly for the rest of the financial year due to sharp price corrections, global demand compression, and inventory overhang.
→Pricing growth likely to be negative with focus on volume-led growth across portfolio.
→Margins remain a priority; improvement targeted via better product mix and pricing actions.
→Long-term growth driven by investments in R&D, product development, manufacturing, and capabilities.
→New product launches and strategic initiatives (e.g., multipurpose plant ramp-up, Difenoconazole commercialization) expected to aid future growth.
→Seed business showing improvement; however, structural skewness towards Kharif season continues.
→International business growth will be gradual, impacted by oversupply and pricing pressures; pendimethalin volumes show positive traction.
→Overall, earnings growth expected to be modest to subdued in the near term with focused efforts to improve quality of sales, cash flows, and collections.

3 more insights locked — sign up free to unlock

Fundraise plans

→No new fundraising through debt or equity is mentioned in the transcript.
→The company has repaid Rs.100 crore of working capital loans during H1 FY24.
→Post this repayment, Rallis India has become a zero-debt company except for a small sales tax deferral loan.
→Capex for the year is envisaged to be around Rs.150 crore, indicating ongoing investments are likely to be funded internally.
→No indication of plans for raising additional capital through equity or new debt issuance was shared during the call.

Order book

The provided transcript and document sections do not mention specific details regarding the current or expected order book or pending orders for the company. Key points related to business performance, challenges, and outlook are discussed, focusing on: - Impact of high channel inventories and pricing pressures in export markets. - Volume declines in international business due to stock liquidation. - Positive developments in certain product lines like Pendimethalin. - Commercialization of new products such as Difenoconazole and contract manufacturing initiatives. - No specific numeric data or commentary on the current order book or pending orders is provided. Therefore, there is no disclosed information on the current or expected order book or pending orders in the excerpts from page 15 or related pages.

Capex plans

Yes

→The company envisages capex spending of around Rs.150 crore for the year.
→Focus on ramping up the multipurpose plant (MPP) at Dahej.
→Continuous evaluation and potential expansion of capacity for Pendimethalin due to rising demand.
→Investments made over the last few years in R&D, product development, manufacturing, and capabilities aimed at supporting long-term sustainable growth.
→Plans to scale up contract manufacturing business progressively through better utilization of the new multi-purpose plant.
→Introduction of new technical products like Difenoconazole and upcoming commercialization of new CSM products from MPP expected to contribute to growth.
→Investment decisions are made with a long-term perspective, considering over 10-year IRR for projects.

How does Rallis India Ltd rank vs peers in Fertilizers & Agrochemicals?

Pro feature

1Rallis India Ltd

Rev 5Mar 3

See full Fertilizers & Agrochemicals sector rankings

Want more stocks like Rallis India Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio